Mark Lewis: The ‘trolley problem’ of adjuvant chemotherapy in colon cancer
Mark Lewis shared a post on X, about paper published in Journal of Clinical Oncology:
Should the Benefit of Adjuvant Chemotherapy in Colon Cancer Be Re-Evaluated?
Authors: Lars A. Pahlman, Werner M. Hohenberger, Klaus Matzel, Kenichi Sugihara, Philip Quirke and Bengt Glimelius.
”Every time I grapple with the ‘trolley problem’ of adjuvant chemotherapy in colon cancer, I return to this manuscript (written in 2016 in Journal of Clinical Oncology and thus preceding many ctDNA-informed approaches but also foretelling the top-heavy risk/benefit of oxaliplatin).”
Source: Mark Lewis/X
Mark Lewis is the Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, the Co-Chair of adolescent and young adult (AYA) oncology in the SWOG cooperative group, and the Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a well-known patient advocate and social media influencer. His interests are neuroendocrine tumors and cancer syndromes.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023